期刊文献+

重组人血小板生成素联合糖皮质激素治疗难治性特发性血小板减少性紫癜的疗效观察 被引量:9

下载PDF
导出
摘要 目的探讨重组人血小板生成素(rhTPO)联合糖皮质激素治疗难治性特发性血小板减少性紫癜(ITP)的疗效。方法将20例难治性ITP患者分为治疗组和对照组,治疗组12例采用rhTPO联合糖皮质激素治疗,对照组8例采用rhTPO治疗,比较两组疗效及不良反应。结果治疗组近期有效率91.7%,对照组100%;停rhTPO后血小板计数逐渐下降,至治疗后30 d,治疗组血小板计数仍明显高于治疗前(<0.01)和同期对照组(<0.05)。停rhTPO治疗3个月后,治疗组中9例患者完全反应(CR)4例,有效(R)3例,无效(NR)2例;对照组中6例患者CR 1例,R3例,NR2例。两组患者对药物耐受良好,无一例终止治疗。结论 rhTPO联合糖皮质激素治疗难治性ITP具有良好的疗效,不良反应轻微。
出处 《现代实用医学》 2013年第4期417-418,422,共3页 Modern Practical Medicine
  • 相关文献

参考文献7

二级参考文献30

  • 1赵永强,王庆余,翟明,徐健,陈协群,刘文励,张梅,宋善俊,王健民,孟凡义,单渊东.重组人血小板生成素治疗慢性难治性特发性血小板减少性紫癜的多中心临床试验[J].中华内科杂志,2004,43(8):608-610. 被引量:102
  • 2范磊,阮长耿.特发性血小板减少性紫癜发病机制[J].江苏医药,2006,32(4):357-359. 被引量:22
  • 3[1]KAUSHANSKY K. Thrombopoietin[J]. N Engl J Med ,1998,339(11):746-754.
  • 4[2]BORGE OJ, RAMSFJELL V, VEIBY OP, et al. Thrombopoietin, but not erythropoietin promotes viability and inhibits apoptosis of multipotent murine hematopoietic progenitor cells in vitro[J]. Blood, 1996, 88(8):2859-2870.
  • 5[3]VADHAN-RAJ S. Recombinant human thrombopoietin in myelosuppressive chemotherapy[J]. Oncology(Huntingt), 2001,15(7 Suppl 8):35-38.
  • 6[4]MURRAY LJ,LUENS KM, ESTRADA MF, et al. Thrombopoietin mobilizes CD34+ cell subsets into peripheral blood and expands multilineage progenitors in bone marrow of cancer patients with normal hematopoiesis[J]. Exp Hematol, 1998, 26(3):207-216.
  • 7[5]VADHAN-RAJ S. Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia[J]. Semin Hematol, 2000, 37(2 Suppl 4):28-34.
  • 8[6]SITNICKA E,LIN N, PRIESTLEY GV, et al. The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells[J]. Blood, 1996, 87(12):4998-5005.
  • 9[1]-[6] See above
  • 10KUTER DJ.Future directions with platelet growth factors[J].Seminar Hemotol,2000,37:41-49.

共引文献69

同被引文献65

  • 1赵永强,王庆余,翟明,徐健,陈协群,刘文励,张梅,宋善俊,王健民,孟凡义,单渊东.重组人血小板生成素治疗慢性难治性特发性血小板减少性紫癜的多中心临床试验[J].中华内科杂志,2004,43(8):608-610. 被引量:102
  • 2中华医学会血液学分会血栓与止血学组.成人ITP诊治的中国专家共识(修订版)[J].中华血液学杂志,2011,32(3):218-219.
  • 3Tripathi AK,Shukla A,Mishra S,et al.Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients[J].Int J Hematol,2014,99(4):413-417.
  • 4Kashiwagi H,Tomiyama Y.Pathophysiology and management of primary immune thrombocytopenia[J].Int J Hematol,2013,98(1):24-33.
  • 5Cines DB,Bussel JB.How I treat idiopathic thrombocytopenic purpura(ITP)[J].Blood,2005,106(7):2244-2251.
  • 6yon dem Borne A,Folman C,van den Oudenrijn S,et al.The potential role of thrombopoietin in idiopathic thrombocytopenic purpura[J].Blood Rev,2002,16(1):57-59.
  • 7Kuter DJ,Begley CG.Recombinant human thrombopoietin:basic biology and evaluation of clinical studies[J].Blood,2002,100(10):3457-3469.
  • 8Bao W,Bussel JB,Heck S,et al.Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents[J].Blood,2010,116(22):4639-4645.
  • 9Canellas CGL,Carvalho SMF,Bellido AVB,et al.Determination of low Z in human serum of patients with idiopathic thrombocytopenic purpura by total reflection X-ray fluorescence[J].X-Ray Spectrometry:An International Journal,2013,42(4):312-315.
  • 10Boyers D,Jia X,Jenkinson D,et al.Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura:A NICE single technology appraisal[J].Pharmaco Economics,2012,30(6):483-495.

引证文献9

二级引证文献77

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部